Church & Dwight: What we're watching for in 2Q26 results

Research evidence excerpt

Church & Dwight: What we're watching for in 2Q26 results

Deutsche Bank

Research

Rating Company Date

Buy Church & Dwight 16 July 2026

North America Reuters Bloomberg Rating Buy

United States CHD.N CHD US Price target (USD) 109.00 Price at 15 Jul 26 97.14

52-week range 260.97 – 81.60

Consumer

Consumer Staples Valuation & Risks

What we're watching for in 2Q26 results

Steve Powers

CHD reports 2Q26 earnings results on Friday, July 31st pre-market Research Analyst

+1-212-250-5480 Approaching CHD's 2Q26 results, our quarterly EPS estimate of $0.88 is

consistent with company guidance, albeit a penny below Street expectations of Christopher Barnes, CFA

$0.89. We forecast organic sales growth of +3.5%, modestly above both company Research Analyst

guidance (+3.0%) and consensus (+3.3%), driven by continued market share +1-212-454-0778

gains, category-leading distribution wins, and strong execution behind key

Nikhil Jain, CFA growth platforms including TheraBreath, Hero, and ARM & HAMMER. Recent Research Associate

tracked channel consumption trends remain healthy (+4.1% for the 13 weeks +1-212-250-3253

ending 6/27 vs. +3.8% in 1Q), though laundry detergent trends did soften

modestly during the quarter (especially June). Even so, we believe the Angeline Goh

combination of innovation, distribution gains, and ongoing strength in oral care Research Associate

+1-212-250-4515

and acne care should support another solid quarter. Touchland should provide a

modest tailwind to reported results, while the recently acquired Miss Mouth

brand remains an emerging longer-term opportunity.

Looking ahead, we expect management to reiterate its FY26 guidance for +3-4%

organic sales growth and +5-8% adjusted EPS growth (implied EPS range of

$3.71-$3.81).